These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22165036)

  • 1. Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency.
    Oviedo-Joekes E; Marsh DC; Guh D; Brissette S; Schechter MT
    J Opioid Manag; 2011; 7(5):371-6. PubMed ID: 22165036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.
    Oviedo-Joekes E; Brissette S; MacDonald S; Guh D; Marchand K; Jutha S; Harrison S; Janmohamed A; Zhang DZ; Anis AH; Krausz M; Marsh DC; Schechter MT
    Drug Alcohol Depend; 2017 Jul; 176():55-62. PubMed ID: 28521199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.
    Marchand KI; Oviedo-Joekes E; Guh D; Brissette S; Marsh DC; Schechter MT
    BMC Health Serv Res; 2011 Jul; 11():174. PubMed ID: 21791093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
    Bansback N; Guh D; Oviedo-Joekes E; Brissette S; Harrison S; Janmohamed A; Krausz M; MacDonald S; Marsh DC; Schechter MT; Anis AH
    Addiction; 2018 Jul; 113(7):1264-1273. PubMed ID: 29589873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.
    Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Harrison S; MacDonald S; Lock K; Anis AH; Marsh DC; Schechter MT
    J Subst Abuse Treat; 2019 Jun; 101():50-54. PubMed ID: 31174713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency.
    Oviedo-Joekes E; Marchand K; Lock K; MacDonald S; Guh D; Schechter MT
    Subst Abuse Treat Prev Policy; 2015 Jan; 10():3. PubMed ID: 25619263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.
    Oviedo-Joekes E; Guh D; Brissette S; Marchand K; MacDonald S; Lock K; Harrison S; Janmohamed A; Anis AH; Krausz M; Marsh DC; Schechter MT
    JAMA Psychiatry; 2016 May; 73(5):447-55. PubMed ID: 27049826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.
    Fairbairn N; Ross J; Trew M; Meador K; Turnbull J; MacDonald S; Oviedo-Joekes E; Le Foll B; Goyer MÈ; Perreault M; Sutherland C
    CMAJ; 2019 Sep; 191(38):E1049-E1056. PubMed ID: 31548191
    [No Abstract]   [Full Text] [Related]  

  • 9. Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder.
    Oviedo-Joekes E; Palis H; Guh D; Marsh DC; MacDonald S; Harrison S; Brissette S; Anis AH; Schechter MT
    J Addict Med; 2019; 13(5):354-361. PubMed ID: 30747750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.
    Palis H; Marchand K; Guh D; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT; Oviedo-Joekes E
    Subst Abuse Treat Prev Policy; 2017 May; 12(1):25. PubMed ID: 28526048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.
    Oviedo-Joekes E; Guh D; Brissette S; Marsh DC; Nosyk B; Krausz M; Anis A; Schechter MT
    J Subst Abuse Treat; 2010 Jun; 38(4):408-11. PubMed ID: 20359843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.
    Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT
    Drug Alcohol Rev; 2018 Jan; 37(1):137-146. PubMed ID: 28593748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment.
    Oviedo-Joekes E; Guh D; Marchand K; Marsh DC; Lock K; Brissette S; Anis AH; Schechter MT
    Subst Abuse Treat Prev Policy; 2014 Jun; 9():23. PubMed ID: 24908387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. History of reported sexual or physical abuse among long-term heroin users and their response to substitution treatment.
    Oviedo-Joekes E; Marchand K; Guh D; Marsh DC; Brissette S; Krausz M; Anis A; Schechter MT
    Addict Behav; 2011; 36(1-2):55-60. PubMed ID: 20855171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans.
    Eydt E; Glegg S; Sutherland C; Meador K; Trew M; Perreault M; Goyer MÈ; Le Foll B; Turnbull J; Fairbairn N
    CMAJ Open; 2021; 9(1):E115-E124. PubMed ID: 33622764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding access to diacetylmorphine and hydromorphone for people who use opioids in Canada.
    Maghsoudi N; Bowles J; Werb D
    Can J Public Health; 2020 Aug; 111(4):606-609. PubMed ID: 32221867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between opioid cross-tolerance during buprenorphine stabilization and return to opioid use during buprenorphine dose tapering.
    Greenwald MK; Sogbesan T; Moses TEH
    Psychopharmacology (Berl); 2024 Jun; 241(6):1151-1160. PubMed ID: 38326506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abuse deterrence testing: A dose ratio escalation study examining naloxone coadministered with intravenous hydromorphone in non-treatment-seeking, opioid-dependent drug users.
    Levy-Cooperman N; Schoedel KA; Reiz JL; Thompson D; Chakaraborty B; Geoffroy P; Michalko KJ
    J Opioid Manag; 2016; 12(3):165-80. PubMed ID: 27435437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiation of injectable opioid agonist treatment in hospital: A case report.
    McAdam M; Brar R; Young S
    Drug Alcohol Rev; 2020 Feb; 39(2):138-141. PubMed ID: 31814186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study.
    Dunn KE; Brands B; Marsh DC; Bigelow GE
    Psychopharmacology (Berl); 2018 Apr; 235(4):971-981. PubMed ID: 29270641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.